Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry 9/10/2009 \| published by: Decision Resources ... on Courts and Competition on July 14, 2009, regarding data exclusivity for biosimilars. We also provide insights from an interviewed health policy lobbyist who is active in government affairs in Washington, D.C. He spoke on ... \| more...	$4,600.00
2005 Chartbook of International Pharmaceutical Prices 12/22/2005 \| published by: Decision Resources ... uncommon. This analysis is intended to fill that void. In this report, we examine overall price differentials among the world's seven largest pharmaceutical markets (the United States,France, Germany, Italy, Spain, the United Kingdom, and Japan) ... \| more...	$4,600.00
2005 News in Review: Important Changes for the Pharmaceutical Industry 12/22/2005 \| published by: Decision Resources ... years to come. The report covers ten important news stories: - The Vioxx withdrawal. - The Tysabri withdrawal. - The approval of BiDil for African-Americans. - Medicare Part D. - The drug reimportation debate. - ... \| more...	$4,600.00
2006 Chartbook of International Pharmaceutical Prices 6/30/2006 \| published by: Decision Resources ... manufacturers to cut their prices. This increasingly price-sensitive environment requires pharmaceutical companies to be aware of international price differentials. In this report, we analyze pharmaceutical prices at the ex-manufacturer level, examining overall price differentials among ... \| more...	$4,600.00
2006 Financings: IPOs and Pharma’s Acquisitions of Private (IPO-less) Companies 12/8/2006 \| published by: Decision Resources ... may feel they are too young to die from an early acquisition, big pharma and private investors have a quite different perspective. Get the Answers You Need to Shape Your Strategy The market for acquiring ... \| more...	$4,600.00
2006 Industry Dynamics: Lessons to Be Learned 12/21/2006 \| published by: Decision Resources ... their opinions and integrated their commentary and analysis into this report. Get the Answers You Need to Shape Your Strategy The winning technology of 2006 continues to be a major success for the drug industry; ... \| more...	$4,600.00
2007 Chartbook of International Pharmaceutical Prices 6/14/2007 \| published by: Decision Resources ... companies increasingly need to be aware of international price differentials. Through 20 tables and 10 fi gures of ex-manufacturer prices of 160 of the world's best-selling prescription drugs sold in seven of the world's largest ... \| more...	$4,600.00
2011's Emerging Blockbusters: Can They Rescue the Declining Blockbuster Model? 11/1/2010 \| published by: Decision Resources ... with little chance of repair. Whether the industry can overcome these obstacles is a matter of debate, but Decision Resources foresees a new crop of potential blockbusters reaching the market in 2011. Our profiles of ... \| more...	$4,600.00
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry 9/15/2009 \| published by: Decision Resources ... rapidly depleting cash reserves, changing sources of growth, the specter of comparative effectiveness, and the threat posed by biosimilars. Staying alive in the short term and creating a more viable way of doing business are ... \| more...	$4,600.00
Advances Imminent in Anti-Angiogenesis Therapeutic 4/1/2005 \| published by: Decision Resources ... road to market. The breakthrough came in 2004 when the FDA approved Genentech's bevacizumab (Avastin) for colon and rectum cancer and Eyetech Pharmaceuticals' pegaptanib (Macugen) for age-related macular degeneration (AMD). Approval of these drugs essentially ... \| more...	$4,600.00
Advances in the Treatment of Serious Systemic Fungal Infections - An Update 3/18/2005 \| published by: Decision Resources ... other conditions. Many strains of fungi are developing resistance to current drugs, especially fluconazole. As this public health problem reaches a crisis, the available drugs (polyenes, azoles, pyrimidines, and the emerging echinocandins) have become inadequate ... \| more...	$4,600.00
Advancing Drug Discovery Through Structure-Guided Drug Design 4/19/2005 \| published by: Decision Resources ... because they are handicapped by technically challenging, often cumbersome technologies. In general, the available tools do not satisfy the demand for rapid delivery of accurate information about pharmaceutically relevant molecules. Consequently, scientists are seeking new ... \| more...	$4,600.00
Age-Related Macular Degeneration 3/1/2010 \| published by: Decision Resources ... predict the market potential of a drug fulﬁlling a key unmet need. This information is critical for evaluating the impact of clinical attributes on physician prescribing of emerging agents, whether the emerging drug is your ... \| more...	$9,200.00
An Exploration of Consolidation in the Generics Industry 12/6/2005 \| published by: Decision Resources ... 1990s and continues into the early part of the 21st century. After the initial flurry of activity in the United States in the early 1990s, U.S. generics companies have shown little recent activity in terms ... \| more...	$4,600.00
An Industry in Crisis: Desperately Seeking New Strategies 6/30/2006 \| published by: Decision Resources ... its once successful blockbuster business model, which has blinded it to new strategies for developing drugs. In this report, we address recent strategies that have failed to help Big Pharma, and we take a hard ... \| more...	$4,600.00
An Industry in Crisis: Fixing Pharma's Damaged Reputation 4/19/2006 \| published by: Decision Resources ... of its stakeholders, whom it serves and upon whom it depends for success. Currently, however, the reputation and integrity of the once-iconic pharma industry are under serious attack. From the end of the 1990s, pharma ... \| more...	$4,600.00
The Anemia Market: Biogenerics and Second-Generation Products Drive Change 3/7/2007 \| published by: Decision Resources ... an opportunity for companies to enter this market with improved alternatives. Get the Answers You Need to Shape Your Strategy Worldwide sales of erythropoiesis-stimulating proteins reached $11.2 billion in 2005, and the market has grown ... \| more...	$4,600.00
Ankylosing Spondylitis: How Have Biological Therapies Affected the Market? 3/23/2009 \| published by: Decision Resources ... Although these agents may establish themselves as the gold-standard treatment for AS, emerging agents can still capitalize on the need for lower-priced, convenient, and effi cacious agents. Thus, the AS market continues to represent an ... \| more...	$4,600.00
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market 4/1/2005 \| published by: Decision Resources ... relatively small patient populations, hospital- acquired drug-resistant infections represent the few remaining areas of high unmet medical need within the antibacterial market. With many Big Pharma companies recently choosing to withdraw from active competition in ... \| more...	$4,600.00
Antitumor Biologics—Strategies for Success in an Expanding Market 9/28/2006 \| published by: Decision Resources ... in 2005-and expanding, the future for such high-cost drugs is fraught with competitive and fi nancial challenges. Get the Answers You Need to Shape Your Strategy Monoclonal antibodies, generating $7.3 billion in sales in 2005, ... \| more...	$4,600.00
Antivirals: Novel Targets, Technologies, and Dealmaking 2/2/2010 \| published by: Decision Resources ... Targeted antivirals have been enormously successful for human immunodeficiency virus (HIV) and include life-saving blockbusters such as Truvada, Atripla, Kaletra, and Reyataz. The HIV pharmacopeia has expanded from drugs that target reverse transcriptase and protease ... \| more...	$4,600.00
The Antivirals Pipeline: Competitive Review 5/3/2010 \| published by: Decision Resources ... reasons that 122 companies are actively involved in clinical development of 139 antiviral agents despite the plethora of available agents. Given the need for therapies that can deal with mutating viruses that render current therapies ... \| more...	$4,600.00
Applications of Stem Cells in Drug Discovery 1/25/2005 \| published by: Decision Resources ... injury, and multiple sclerosis, as well as organ transplantation and wound treatment. Stem cells are also a valuable source of material in drug discovery, high-content screening assays, and toxicology studies. In this report, we discuss ... \| more...	$4,600.00
Are Biologics the Wave of the Future? 3/30/2007 \| published by: Decision Resources ... wave that began 25 years ago while others were left behind. Big pharma, in particular, has taken a long time to recognize the vital importance of biologics in today's marketplace. Big pharma is now on ... \| more...	$4,600.00
Are Genomic and Proteomic Patents Hindering Drug Development? 11/9/2006 \| published by: Decision Resources ... therapies? Going forward, how can various players in this field accommodate confl icting business needs and forge mutually agreeable collaborations? Get the Answers You Need to Shape Your Strategy Business strategies in the biotech, diagnostic, ... \| more...	$4,600.00

< prev 1 2 3 4 5 6 7 8 9 10 next >